PMID- 27900103
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220317
IS  - 2049-9450 (Print)
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Linking)
VI  - 5
IP  - 5
DP  - 2016 Nov
TI  - Muscle wasting associated with the long-term use of mTOR inhibitors.
PG  - 641-646
AB  - Some targeted therapies alter muscle mass due to interference with pathways of 
      muscle metabolism. The effects of mammalian target of ra pamycin (mTOR) 
      inhibitors on muscle mass have yet to be fully elucidated. In the present study, 
      the computerized tomography (CT) scans of patients receiving mTOR inhibitors for 
      at least 6 months taken at baseline and post-therapy were retrospectively 
      retrieved, and body composition analyses were performed using the software, 
      sliceOmatic version 5.0 (TomoVision, Inc., Magog, QC, Canada). The difference in 
      body composition parameters was evaluated for significance. The time to treatment 
      (TTF) failure was also compared between the sarcopenic and non-sarcopenic 
      patients at the baseline. Of the 75 patients studied, 20 matched the inclusion 
      criteria (including 16 males). The mean duration between the CT scans was 
      14.4+/-2.0 months. A total of 12 (60%) patients were sarcopenic at the baseline, 
      whereas three more (75% in total) became sarcopenic following treatment. The use 
      of mTOR inhibitors significantly decreased the skeletal muscle area (P=0.011) and 
      lean body mass (P=0.007), although it had no effect on adipose tissue (P=0.163) 
      or body weight (P=0.262). The rate of skeletal muscle wasting was 2.6 cm(2)/m(2), 
      or 2.3 kg in 6 months. The TTF did not differ between sarcopenic and 
      non-sarcopenic patients, and was not significantly associated with any other 
      parameter. To the best of our knowledge, this is the first study to demonstrate 
      that the long-term use of mTOR inhibitors induces a marked loss of muscle mass. 
      Due to the predictive and prognostic role of sarcopenia in cancer patients, these 
      findings may have important clinical implications.
FAU - Gyawali, Bishal
AU  - Gyawali B
AD  - Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 
      Nagoya, Aichi 466-8560, Japan.
FAU - Shimokata, Tomoya
AU  - Shimokata T
AD  - Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 
      Nagoya, Aichi 466-8560, Japan.
FAU - Honda, Kazunori
AU  - Honda K
AD  - Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 
      Nagoya, Aichi 466-8560, Japan.
FAU - Kondoh, Chihiro
AU  - Kondoh C
AD  - Department of Medical Oncology, Japanese Red Cross Nagoya Daiichi Hospital, 
      Nagoya, Aichi 453-8511, Japan.
FAU - Hayashi, Naomi
AU  - Hayashi N
AD  - Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 
      Nagoya, Aichi 466-8560, Japan.
FAU - Yoshino, Yasushi
AU  - Yoshino Y
AD  - Department of Urology, Nagoya University Graduate School of Medicine, Nagoya 
      University Hospital, Nagoya, Aichi 466-8560, Japan.
FAU - Sassa, Naoto
AU  - Sassa N
AD  - Department of Urology, Nagoya University Graduate School of Medicine, Nagoya 
      University Hospital, Nagoya, Aichi 466-8560, Japan.
FAU - Nakano, Yasuyuki
AU  - Nakano Y
AD  - Department of Medical Oncology, Japanese Red Cross Nagoya Daiichi Hospital, 
      Nagoya, Aichi 453-8511, Japan.
FAU - Gotoh, Momokazu
AU  - Gotoh M
AD  - Department of Urology, Nagoya University Graduate School of Medicine, Nagoya 
      University Hospital, Nagoya, Aichi 466-8560, Japan.
FAU - Ando, Yuichi
AU  - Ando Y
AD  - Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 
      Nagoya, Aichi 466-8560, Japan.
LA  - eng
PT  - Journal Article
DEP - 20160913
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC5103886
OTO - NOTNLM
OT  - cancer cachexia
OT  - mTOR inhibitors
OT  - mammalian target of rapamycin
OT  - sarcopenia
OT  - skeletal muscle index
OT  - skeletal muscle mass
EDAT- 2016/12/03 06:00
MHDA- 2016/12/03 06:01
PMCR- 2016/09/13
CRDT- 2016/12/01 06:00
PHST- 2016/05/18 00:00 [received]
PHST- 2016/08/10 00:00 [accepted]
PHST- 2016/12/01 06:00 [entrez]
PHST- 2016/12/03 06:00 [pubmed]
PHST- 2016/12/03 06:01 [medline]
PHST- 2016/09/13 00:00 [pmc-release]
AID - MCO-0-0-1015 [pii]
AID - 10.3892/mco.2016.1015 [doi]
PST - ppublish
SO  - Mol Clin Oncol. 2016 Nov;5(5):641-646. doi: 10.3892/mco.2016.1015. Epub 2016 Sep 
      13.